The Evolving AML Genomic Landscape: Therapeutic Implications

Author(s): Sachi Horibata*, George Alyateem, Christin B. DeStefano, Michael M. Gottesman*

Journal Name: Current Cancer Drug Targets

Volume 20 , Issue 7 , 2020

Become EABM
Become Reviewer

Graphical Abstract:


Improved understanding of the genomic and molecular landscape of acute myeloid leukemia (AML) has resulted in a significant evolution of our understanding of AML biology and allows refined prognostication for those receiving standard combination chemotherapy induction. This dramatic increase in knowledge preceded, and was somewhat responsible for, at least some of eight new FDA drug approvals for AML. This review discusses the impact of genomics on clinical care of AML patients and highlights newly approved FDA drugs. Despite these recent clinical advances, however, the outcome for most patients diagnosed with AML remains dire. Thus, we describe here some of the challenges identified with treating AML including off-target toxicity, drug transporters, clonal heterogeneity, and adaptive resistance, and some of the most promising opportunities for improved therapy.

Keywords: Acute myeloid leukemia (AML), genomic landscape, therapeutics, clinical implications, hematologic malignancy, drug transporters.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2020
Page: [532 - 544]
Pages: 13
DOI: 10.2174/1568009620666200424150321
Price: $65

Article Metrics

PDF: 19